Converting-Enzyme Inhibitors in the Treatment of Hypertension

New England Journal of Medicine

Volumn 319, Issue 23, 1988, Pages 1517-1525

  Oates, John A ^a   Wood, Alastair J j ^a   Williams, Gordon H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALACEPRIL; CAPTOPRIL; ENALAPRIL; LISINOPRIL; PENTOPRIL; RAMIPRIL;

HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMAN; HYPERTENSION;

EID: 0024246261     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198812083192305     Document Type: Review

References (102)

1. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196: 441–4.
2. Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother 1965; 24: 163–9.
3. Vidt DG, Bravo EL, Fouad FM. Captopril. N Engl J Med 1982; 306: 214–9.
4. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198–248.
5. Brunner HR, Nussberger J, Waeber B. The present molecules of converting enzyme inhibitors. J Cardiovasc Pharmacol 1985; 7: Suppl 1: S2–S11.
6. Gomez HJ, Cirillo VJ, Moncloa F. The clinical pharmacology of lisinopril. J Cardiovasc Pharmacol 1987; 9: Suppl 3: S27–S34.
7. Ball SG, Robertson JI. Clinical pharmacology of ramipril. Am J Cardiol 1987; 59: 23D–27D.
8. Rakhit A, Hurley ME, Tipnis V, Coleman J, Rommel A, Brunner HR. Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting enzyme inhibitor in humans. J Clin Pharmacol 1986; 26: 156–64.
9. Onoyama K, Kumagai H, Nanishi F, et al. Pharmacokinetic properties of a new angiotensin I converting enzyme inhibitor (alacepril) in normal office workers. Curr Ther Res 1986; 40: 543–50.
10. Schaller MD, Waeber B, Nussberger J, Brunner HR. Initial evaluation of the angiotensin converting enzyme inhibitor CGS 13945 in hypertensive patients. Curr Ther Res 1985; 37: 843–52.
11. Williams GH, Dluhy RG. Control of aldosterone secretion. In: Genest J, Kuchel O, Hamet P, Cantin M, eds. Hypertension: physiopathology and treatment. 2nd ed. New York: McGraw Hill, 1983:320–38.
12. Wong PY, Talamo RC, Williams GH, Colman RW. Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest 1975; 55: 691–8.
13. Mersey JH, Williams GH, Hollenberg NK, Dluhy RG. Relationship between aldosterone and bradykinin. Circ Res 1977; 40: Suppl I-84–I-88.
14. Proud D, MacGlashan DW Jr, Newball HH, Schulman ES, Lichtenstein IM. Immunoglobin E-mediated release of a kininogenase from purified human lung mast cells. Am Rev Respir Dis 1985; 132: 405–8.
15. Kaufman MP, Baker DG, Coleridge HM, Coleridge JC. Stimulation by bradykinin of afferent vagal C-fibers with chemosensitive endings in the heart and aorta of the dog. Circ Res 1980; 46: 476–84.
16. Blumberg AL, Denny SE, Marshall GR, Needleman P. Blood vessel-hormone interactions: angiotensin, bradykinin, and prostaglandins. Am J Physiol 1977; 232: H305–H310.
17. McGiff JC, Terragno NA, Malik KU, Lonigro AJ. Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res 1972; 31: 36–43.
18. Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991–5.
19. Given BD, Taylor T, Hollenberg NK, Williams GH. Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 1984; 6: 436–41.
20. Swartz SL, Williams GH, Hollenberg NK, Moore TJ, Dluhy RG. Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1979; 1: 106–11.
21. Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 20: 409–52.
22. Shoback DM, Williams GH, Swartz SL, Davies RO, Hollenberg NK. Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 1983; 5: 1010–8.
23. Shionoiri H, Gotoh E, Miyazaki N, et al. Serum concentration and effects of a single dose of enalapril maleate in patients with essential hypertension. Jpn Circ J 1985; 49: 46–51.
24. Odya CE, Wilgis FP, Walker JF. Oparil S. Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension — before and after treatment with enalapril (MK 421). J Lab Clin Med 1983; 102: 714–21.
25. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest 1980; 65: 1257–64.
26. Oparil S, Horton R, Wilkins LH, et al. Antihypertensive effect of enalapril (MK 421) in low renin essential hypertension: role of vasodilator prostaglandins. J Lab Clin Med (in press).
27. Mimran A, Targhetta R, Laroche B. The antihypertensive effect of captopril: evidence for an influence of kinins. Hypertension 1980; 2: 732–7.
28. Moore TJ, Crantz FR, Hollenberg NK, et al. Contribution to prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981; 3: 168–73.
29. Antonaccio MJ, Kerwin L. Pre- and post-junctional inhibition of vascular sympathetic function by captopril in SHR: implication of vascular angiotensin II in hypertension and antihypertensive actions of captopril. Hypertension 1981; 3: Suppl I: I-54–I-62.
30. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59: 59A–65A.
31. Unger T, Ganten D, Lang RE, Scholkens BA. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1984; 6: 872–80.
32. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982; 220: 63–9.
33. Heavey DJ, Reid JL. The effect of SQ 14225 on baroreceptor reflex sensitivity in conscious normotensive rabbits [proceedings]. Br J Pharmacol 1978; 64: 389P–390P.
34. Fouad FM, Tarazi RC, Bravo EL. Cardiac and haemodynamic effects of enalapril. J Hypertens [Suppl] 1983; 1: 135–42.
35. Reid JL, Millar JA, Campbell BC. Enalapril and autonomic reflexes and exercise performance. J Hypertens [Suppl] 1983; 1: 129–34.
36. Guidicelli JF, Berdeaux A, Edouard A, Richer C, Jacolot D. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. Br J Clin Pharmacol 1985; 20: 211–8.
37. Ajayi AA, Campbell BC, Meredith PA, Kelman AW, Reid JL. The effect of captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol 1985; 20: 17–25.
38. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frohlich hlich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105–8.
39. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984; 53: 1044–9.
40. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023–38.
41. Sassano P, Chatellier G, Billaud E, Alhenc-Gelas F, Corvol P, Ménard J. Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril: results of a six-month double-blind trial. Am J Med 1987; 83: 227–35.
42. Bolzano K, Arriaga J, Bemal R, et al. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1987; 9: Suppl 3: S43–S47.
43. Morlin C, Baglivo H, Boeijinga JK. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol 1987; 9: Suppl 3: S49–S52.
44. Pool JL, Gennari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987; 9: Suppl 3: S36–S42.
45. Lessem JN, Rucinska E, Vickers FFsé J, Sromovsky JA. Long-term enalapril — a new converting enzyme inhibitor — in the treatment of mild to moderate hypertension: results of a worldwide multiclinic study: comparing two ways of analyzing data. Clin Exp Hypertens [A] 1985; 7: 1515–39.
46. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7: Suppl 1: S52S55.
47. Corea L, Bentivogiio M, Verdecchia P, Provvidenza M. Converting enzyme inhibition vs diuretic therapy as first therapeutic approach to the elderly hypertensive patient. Curr Ther Res 1984; 36: 347–51.
48. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64.
49. Vidt DG. A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. J Hypertens [Suppl] 1984; 2: S81–S88.
50. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch lntem Med 1984; 144: 1947–53.
51. Andren L, Karlberg BE, Svensson A, Ohman P, Nilsson OR, Hansson L. Long-term effects of captopril and atenolol in essential hypertension. Acta Med Scand 1985; 217: 155–60.
52. Helgeland A, Str⊘mmen R, Hagelund CH, Tretli S. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. Lancet 1986; 1: 872–5.
53. van Schaik BA, Geyskes GG, Kettner N, Boer P, Dorhout-Mees EJ. Comparison of enalapril and propranolol in essential hypertension. Eur J Clin Pharmacol 1986; 29: 511–6.
54. Enalapril in essential hypertension: a comparative study with propranolol: enalapril in Hypertension Study Group (UK). Br J Clin Pharmacol 1984; 18: 51–6.
55. Zachariah PK, Bonnet G, Chrysant SG, et al. Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. J Cardiovasc Pharmacol 1987; 9: Suppl 3: S53–S58.
56. Vlasses PH, Conner DP. Rotmensch HH, et al. Double-blind comparison of captopril and enalapril in mild to moderate hypertension. J Am Coll Cardiol 1986; 7: 651–60.
57. Thind GS, Johnson A, Bhatnagar D, Henkel TW. A parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertension. Am Heart J 1985; 109: 852–8.
58. Garanin G. A comparison of once-daily antihypertensive therapy with captopril and enalapril. Curr Ther Res 1986; 40: 567–75.
59. Chrysant SG, Bal IS, Johnson B, McPherson M. A comparative study of captopril and enalapril in patients with severe hypertension. J Clin Pharmacol 1985; 25: 149–51.
60. Lewis RA, Baker KM, Ayers CR, Weaver BA, Lehman MR. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects. J Cardiovasc Pharmacol 1985; 7: Suppl 1: S12–S15.
61. White WB, Viadero JJ, Lane TJ, Podesla S. Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 1986; 39: 43–8.
62. Singer DR, Markandu ND, Shore Achéal, MacGregor GA. Captopril and nifedipine in combination for moderate to severe essential hypertension. Hypertension 1987; 9: 629–33.
63. Havelka J, Boerlin HJ, Studer A, et al. Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol 1982; 14: Suppl 2: S71–S76.
64. Walker JF, Kulaga SF, Kramsch DM. The efficacy and safety of enalapril in moderate to severe essential hypertension. J Hypertens [Suppl] 1984; 2: S107–S111.
65. Drayer JI, Weber MA, Lipson JL, Megaffin BB. Differential effects of diuresis and beta-adrenoreceptor blockade during angiotensin-converting enzyme inhibition in patients with severe hypertension. J Clin Pharmacol 1982; 22: 179–86.
66. Muiesan G, Alicandri C, Agabiti-Rosei E, et al. A multicenter trial of low dose captopril administered twice daily in patients with essential hypertension unresponsive to beta blocker-diuretic treatment. J Clin Hypertens 1987; 3: 144–52.
67. Reyes AJ, Leary WP, Acosta-Barrios TN. Once-daily administration of captopril and hypotensive effects. J Cardiovasc Pharmacol 1985; 7: Suppl 1: S16–S19.
68. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375–80.
69. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–20.
70. Björk S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471–4.
71. Hommel E, Parving H-H, Mathiesen E, Edsberg B, Damkjaer-Nielsen M, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986; 293: 467–70.
72. Marre M, Leblanc H, Suarez L, Guyenne T-T, Ménard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 1987; 294: 1448–52.
73. Stine SM, Yang H-Y, Costa E. Inhibition of in situ metabolism of [3H] (met5)-enkephalin and potentiation of (met5)-enkephalin analgesia by captopril. Brain Res 1980; 188: 295–9.
74. Singhvi SM, Duchin KL, Willard DA, McKinstry DN, Migdalof BH. Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 1982; 32: 182–9.
75. Hood S, Nicholls MG, Gilchrist NL. Cough with angiotensin converting-enzyme inhibitors. NZ Med J 1987; 100: 6–7.
76. Inman WHW. Enalapril-induced cough. Lancet 1986; 2: 1218.
77. Israel-Biet D. Delaisements C, Chretien J. Enalapril-induced cough. Lancet 1986; 2: 918.
78. Hallwright GP. Maling TB, Town GI. Enalapril and cough: case report. N Z Med J 1986; 99: 66–7.
79. Semple PF. Herd GW. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med 1986; 314: 61.
80. Nash DT. Lisinopril cough. Postgrad Med 1986; 80: 40.
81. Gavras H. A multicenter trial of enalapril in the treatment of essential hypertension. Clin Ther 1986; 9: 24–38.
82. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. Br Med J 1987; 294: 1521–3.
83. DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Med Toxicol 1986; 1: 122–41.
84. Dixon CM, Fuller RW, Barnes PJ. The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects. Br J Clin Pharmacol 1987; 23: 91–3.
85. Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncloa F. Enalapril worldwide experience. Am J Med 1984; 77: Suppl 2A: 23–35.
86. Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Am J Med 1986; 81: Suppl 4C: 46–50.
87. Cooper RA. Captopril-associated neutropenia: who is at risk? Arch Intern Med 1983; 143: 659–60.
88. Erslev AJ, Alexander JC, Caro J, Boyd RL. Hematologic side effects of captopril and associated risk factors. Cardiovasc Rev Rep 1982; 3: 660–71.
89. Jenkins Achéal, Dreslinski GR, Tadros SS, Groel JT, Frand R, Herszeg SA. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 1985; 7: Suppl 1: S96–S101.
90. Moncloa F, Sromovsky JA, Walker JF, Davies RO. Enalapril in hypertension and congestive heart failure: overall review of efficacy and safety. Drugs 1985; 30: Suppl 1: 82–9.
91. McFate-Smith W, Kulaga SF, Moncloa JF, Pingeon R, Walker JF. Overall tolerance and safety of enalapril. J Hypertens [Suppl] 1984; 2: S113–S117.
92. Edwards IR, Coulter DM, Beasley DM, Macintosh D. Captopril: 4 years of post marketing surveillance of all patients in New Zealand. Br J Clin Pharmacol 1987; 23: 529–36.
93. Goodfield MJ, Millard LG. Severe cutaneous reactions to captopril. Br Med J 1985; 290: 1111.
94. Kubo SH, Cody RJ. Enalapril, a rash, and captopril. Ann Intern Med 1984; 100: 616.
95. Zubenko GS, Nixon RA. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 1984; 141: 110–1.
96. Das S, Chatterjee TK, Ghosh JJ. Adrenal involvement in captopril-induced potentiation in morphine analgesia. Eur J Pharmacol 1982; 85: 217–20.
97. Cohen LM, Anderson G, White RF, Griffing G, Melby J. Enalapril and hypertension. Am J Psychiatry 1984; 141: 1012–3.
98. Olajide D, Lader M. Psychotropic effects of enalapril maleate in normal volunteers. Psychopharmacology (Berlin) 1985; 86: 374–6.
99. McMahon T. Bipolar affective symptoms associated with use of captopril and abrupt withdrawal of pargyline and propranolol. Am J Psychiatry 1985; 142: 759–60.
100. Dahlöf B, Andrén L, Eggertsen R, Jern S, Svensson A, Hansson L. Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide. J Hypertens [Suppl] 1985; 3: S483–S486.
101. Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5: Suppl III: III-132–III-138.
102. Hricik DE, Browning PJ, Kopelman R. Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373–6.